Loading...
The risk for relapse among women who become pregnant while in remission from Hodgkin lymphoma (HL) after initial chemotherapy has been unclear. To resolve this issue, investigators studied all women in the Swedish Cancer Registry between 1992 and 2009 who were 18 to 40 years of age at initial HL diagnosis and in complete remission more than 6 months after diagnosis.
Patients received MOPP-ABVD (mechlorethamine, vincristine, procarbazine, prednisone, adriamycin, bleomycin, vinblastine, and dacarbazine) until 1998, after which they received ABVD or, in some high-risk cases, BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone). Pregnancy data was obtained from the Swedish Medical Birth Registry…